Led · Seed · May 2026

Shyld AI develops autonomous physical agents and an edge-native foundation model called VERTEX that run on devices inside hospital rooms to perceive, reason, and take real-time operational actions. Its flagship solution combines AI with UV-C disinfection technology to autonomously disinfect hospital environments and target healthcare-associated infections; a Stanford study published in the American Journal of Infection Control reported the system reduced contamination by more than 93% compared to a control room. The company positions its approach as "Active AI," moving beyond passive ambient models to execute tasks like optimizing disinfection timing, identifying missing supplies, and reducing surgical schedule bottlenecks. Shyld AI is deployed across hospitals nationwide and says its technology reduces administrative burden on clinical and environmental services teams. Founded by Mohammad and Morteza Noshad and based in Sunnyvale, the company plans to use new funding to accelerate U.S. health system deployments and expand into additional regulated clinical and industrial applications. The announcement did not disclose revenue or valuation details.

Participated · Series B · Jan 2026

EpiBiologics is a San Mateo–based biotechnology company pioneering the degradation of disease-driving extracellular membrane and soluble proteins via its proprietary EpiTAC bispecific antibody platform. The company’s lead candidate, EPI-326, is designed to degrade all oncogenic forms of EGFR in a tumor-selective manner, aiming to overcome safety and resistance limitations of current EGFR therapies. Preclinical data show strong, durable efficacy with favorable safety and pharmacokinetic profiles, supporting both monotherapy and combination use across multiple cancer types. EpiBiologics plans to commence a first-in-human trial of EPI-326 in early 2026 for non-small cell lung cancer and head and neck squamous cell carcinoma. Proceeds from its recent financing will also expand a broader pipeline in oncology and immunology while bolstering internal capabilities. The company recently strengthened its leadership team by hiring Eric Humke, M.D., Ph.D., as Chief Medical Officer and Aaron Mishel as Chief Financial Officer, and added several industry leaders to its Board.